AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06455969
Drug: Goserelin 3.6 MG
RxNorm normalized name: goserelin 3.6 MG
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.
Trial: NCT00002289
Drug: Thymopentin
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05324124
Drug: Selpercatinib
RxNorm normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally.
Trial: NCT05596227
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction of anesthesia will be by IV propofol (2-2.5 mg/kg)
Trial: NCT05596227
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium will be injected during induction of anesthesia (0.6 mg/ kg)
Trial: NCT05596227
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane inhalationa anesthesia will be used for maintainance of anesthesia
Trial: NCT06023199
Drug: Voxelotor
RxNorm normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Voxelotor is administered orally at a dose of 1500mg daily.
Trial: NCT05536271
Drug: Bisoprolol Fumarate
RxNorm normalized name: Bisoprolol Fumarate
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: antihypertensive medicine prescribed for acute coronary syndrome patients
Trial: NCT04756336
Drug: LTX-109 gel, 3% w/w
DrugBank: LTX-109 (DB12711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug is applied to affected lesions according to treatment regimen
Trial: NCT05468047
Drug: Ketamine hydrochloride injection
RxNorm normalized name: Ketamine Hydrochloride Injection
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individuals will be administered a single dose of sub-anesthetic (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection intramuscularly as part of a ketamine-assisted therapy experience.
Trial: NCT05034952
Drug: VX-548
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT05972954
Drug: OMT-28
RxNorm normalized name: Omtryg
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT05351437
Drug: MTx-COVAB36
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.
Trial: NCT06416930
Drug: Cadonilimab Combined with chemotherapy
RxNorm normalized name: miconazole
DrugBank: Cadonilimab (DB16680)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cadonilimab (15mg/kg, intravenous drip, D1) + gemcitabine (1250mg/m2, intravenous drip, D1/D8) or vinorelbine (30mg, oral, tiw, D1/D3/D5) or pemetrexed (500mg/m2, intravenous drip, D1), every 3 weeks.
Trial: NCT05468073
Drug: Proleukin
RxNorm normalized name: Proleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks
Trial: NCT05553938
Drug: Empagliflozin 10 mg
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 10mg
Trial: NCT05117307
Drug: Bupivacaine 0.25% Injectable Solution
RxNorm normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided block with 20 ml %0.25 bupivacaine, per side
Trial: NCT05286931
Drug: Ciprofloxacin 500 mg
RxNorm normalized name: ciprofloxacin 500 MG
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 MG, taken once orally.
Trial: NCT06049901
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide is considered a broad-spectrum anti-microbial drug with a potent activity against various helminths, anaerobic bacteria and viruses.
Trial: NCT05692739
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see arm description
Trial: NCT05692739
Drug: Cyclosporins
RxNorm normalized name: Cyclosporine
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arm description
Trial: NCT05692739
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see arm description
Trial: NCT04938102
Drug: Botulinum Toxin Type A Injection [Botox]
RxNorm normalized name: botulinum toxin type A Injection [Botox]
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection of 100 units of botulinum toxin into the lower esophageal sphincter (25 units in each quadrant).
Trial: NCT04672707
Drug: Bromhexine Hydrochloride Tablet
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg
Trial: NCT04672707
Drug: Bromhexine Hydrochloride Tablet
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 mg
Trial: NCT04672707
Drug: Bromhexine Hydrochloride Tablet
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64 mg
Trial: NCT04672707
Drug: Bromhexine Hydrochloride Tablet
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80mg
Trial: NCT05117294
Drug: Bocidelpar
RxNorm normalized name: Bocidelpar
DrugBank: Bocidelpar (DB16906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04802122
Drug: Sevoflurane inhalant product
RxNorm normalized name: sevoflurane Inhalant Product
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane 8% / O2 100% with the vital capacity breathing method (vital capacity induction, VCI) will be used for induction to anesthesia and facilitate endotracheal intubation.
Trial: NCT04802122
Drug: Propofol Fresenius
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 1,5mg/Kg, supplemented by fentanyl 2mcg/Kg and rocuronium 0,5mg/Kg and O2 100% will be for induction to anesthesia and facilitate endotracheal intubation. .
Trial: NCT05872451
Drug: Rocuronium Bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After measuring the initial current intensity, quantitative neuromuscular blockade monitoring is applied, and rocuronium (0.6 mg/kg) is administered.
Trial: NCT04795427
Drug: asciminib
RxNorm normalized name: Asciminib
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily
Trial: NCT05409066
Drug: Epcoritamab
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT05409066
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous Infusion
Trial: NCT05409066
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Capsules
Trial: NCT05206279
Drug: Ureteral injection of Indocyanine Green Powder (diluted)
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The intervention we study is the intraureteral injection of ICG during a laparoscopic deep infiltrative endometriosis resection procedure. Cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
Trial: NCT05217537
Drug: Omadacycline Injection [Nuzyra]
RxNorm normalized name: omadacycline Injection [Nuzyra]
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 100 mg omadacycline IV in 100 mL of normal saline
Trial: NCT05217537
Drug: Omadacycline Oral Tablet
RxNorm normalized name: omadacycline Oral Tablet
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)
Trial: NCT06652087
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) in standard doses of 200 mg 3 times a day for 7 days
Trial: NCT04794049
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In experiment cohort, patients do not use standard bowel preparation regimen, they totally drink 300ml lactulose.
Trial: NCT04794049
Drug: Polyethylene Glycol (PEG)
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In control cohort, patients use the standard split-dose bowel preparation regimen,
Trial: NCT05077033
Drug: phIL12 GET
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intratumoral phIL12 gene electrotransfer
Trial: NCT05543226
Drug: PHGG-rich enteral nutrtiion
RxNorm normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHGG-rich enteral nutrition
Trial: NCT04195776
Drug: Tenofovir Douche
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 660 mg TFV in 125 mL hypo-osmolar solution
Trial: NCT04832100
Drug: Pregabalin 150mg, imipramine 25mg
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conventional treatment for fibromyalgia was given to patients. Clinical follow-ups with questionnaires and interview were arranged then.
Trial: NCT05021640
Drug: DCR-AUD
RxNorm normalized name: DCR-PHXC free acid
DrugBank: Nedosiran (DB17635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
Trial: NCT05284552
Drug: Tinzaparin Injectable Solution
RxNorm normalized name: tinzaparin Injectable Solution
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT06262581
Drug: Tisleizumab(BGB-A317)
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg i.v. q3w
Trial: NCT06067191
Drug: RV299
RxNorm normalized name: Ravulizumab
DrugBank: Ravulizumab (DB11580)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Suspension
Trial: NCT05527301
Drug: Lactobacillus Fermentum
RxNorm normalized name: Lactobacillus Fermentum
DrugBank: Lactobacillus fermentum (DB16542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus Fermentum
Trial: NCT05621525
Drug: BBP-398
RxNorm normalized name: BBP-812
DrugBank: BBP-812 (DB16983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
Trial: NCT06124001
Drug: camrelizumab for Injection
RxNorm normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered once at 3 mg/kg intravenously on Days 8 of each cycle.
Trial: NCT05491460
Drug: Apixaban 5 MG Tab
RxNorm normalized name: apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral intake
Trial: NCT05491460
Drug: Dabigatran 150 MG Tab
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral intake
Trial: NCT05491460
Drug: Edoxaban 60Mg Tab
RxNorm normalized name: EDOXABAN 60MG TAB
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral intake
Trial: NCT05491460
Drug: Rivaroxaban 20 MG Tab
RxNorm normalized name: rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral intake
Trial: NCT05140148
Drug: Amantadine
RxNorm normalized name: Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease
Trial: NCT05041257
Drug: Mirvetuximab soravtansine
RxNorm normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous (IV) infusion on Day 1 of every 3-week cycle
Trial: NCT06452654
Drug: Sodium Chloride 0.9% Inj
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaccination
Trial: NCT06564844
Drug: Datopotamab Deruxtecan
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Datopotamab Deruxtecan IV (intravenous)
Trial: NCT06564844
Drug: Rilvegostomig
RxNorm normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilvegostomig IV (intravenous)
Trial: NCT06564844
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin IV (intravenous), Active Comparator
Trial: NCT04101838
Drug: Fluzone
RxNorm normalized name: Fluzone
DrugBank: Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (DB10791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactivated seasonal influenza vaccine
Trial: NCT06564844
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin IV (intravenous), Active Comparator
Trial: NCT06564844
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide IV (intravenous), Active Comparator
Trial: NCT06564844
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed IV (intravenous), Active Comparator
Trial: NCT04101838
Drug: Flucelvax
RxNorm normalized name: Flucelvax
DrugBank: Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated) (DB10998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactivated seasonal influenza vaccine
Trial: NCT04101838
Drug: Fluzone High-Dose
RxNorm normalized name: Fluzone High-Dose
DrugBank: Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (DB10791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactivated seasonal influenza vaccine
Trial: NCT04101838
Drug: Fluad
RxNorm normalized name: FLUAD 2015-2016
DrugBank: Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (formaldehyde inactivated) (DB10792)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactivated seasonal influenza vaccine
Trial: NCT06326112
Drug: Furosemide Injection
RxNorm normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: o.5 mg/kg bid or tid IV
Trial: NCT06326112
Drug: Metolazone Tablets
RxNorm normalized name: Metolazone Tablets
DrugBank: Metolazone (DB00524)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diuretic as needed
Trial: NCT06564844
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine IV (intravenous), Active Comparator
Trial: NCT06564844
Drug: UFT
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT Oral route of administration, Active Comparator
Trial: NCT05334056
Drug: Cocaine Nasal
RxNorm normalized name: cocaine nasal
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 4% cocaine given as a nasal spray immediately prior to nasal intubation
Trial: NCT05849480
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin (130 mg/m2) will be administered IV on Day 1 of each cycle, every 21 days (up to 6 cycles).
Trial: NCT05033392
Drug: Toripalimab Injection
RxNorm normalized name: toripalimab Injection
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A domestic PD-1 antibody
Trial: NCT05669989
Drug: Isatuximab intravenous (IV)
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Route of administration: IV infusion; Pharmaceutical form: Vial
Trial: NCT05669989
Drug: Cemiplimab (SAR439684)
RxNorm normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Route of administration: IV infusion; Pharmaceutical form: Vial
Trial: NCT05669989
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: Oral or IV infusion; Pharmaceutical form: Tablets/single use vial
Trial: NCT05669989
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Route of administration: Oral; Pharmaceutical form: Capsules
Trial: NCT05669989
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: Oral; Pharmaceutical form: Hard capsules
Trial: NCT05669989
Drug: Isatuximab subcutaneous (SC)
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Route of administration: SC injection with the investigational isatuximab injector device; Pharmaceutical form: Vial
Trial: NCT05669989
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: IV infusion; Pharmaceutical form: Vial
Trial: NCT04856917
Drug: Imsidolimab
RxNorm normalized name: Imsidolimab
DrugBank: Imsidolimab (DB16658)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized Monoclonal Antibody
Trial: NCT05324904
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Vitamin D~* The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,~* Using a 27-gauge syringe with the bevel facing upward, a maximum of 0.6 ml (60,000 IU) of vitamin D3 solution will be slowly injected into the base of the largest plantar wart (large warts \> 10 mm need multiple injections at different sites)~* Treatment sessions will be performed at 3-week intervals for a maximum of 4 sessions
Trial: NCT05324904
Drug: acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -Acyclovir~* Acyclovir vial (Zovirax® vial, 250mg, ) will be diluted with 3.5 ml saline to get approximately 70 mg /ml solution.~* After sterilization of the skin, a 27-gauge syringe with the bevel facing upward will be inserted into the base of the largest plantar wart to slowly inject the solution~* Treatment sessions will be performed at 2-week intervals for maximum of 5 sessions
Trial: NCT05067166
Drug: Ansuvimab
RxNorm normalized name: Ansuvimab
DrugBank: Ansuvimab (DB16385)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single infusion 50 mg/kg IV
Trial: NCT04999137
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses
Trial: NCT04999137
Drug: Vitamin B1
RxNorm normalized name: Vitamin B1
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses
Trial: NCT06393816
Drug: Durvalumab with etoposide and Carboplatin/Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination of durvalumab with etoposide and Carboplatin/Cisplatin as First Line Treatment in Patients With Large-cell Neuroendocrine Carcinomas of the Lung.~All patients (either with confirmed diagnosis or not) will be treated and followed-up:~* During the induction: every 3 weeks for 12 weeks (4 cycles)~* During the maintenance: every 4 weeks for 24 months